Navigation Links
APT Pharmaceuticals Completes Enrollment in Phase III for Inhaled Cyclosporine
Date:2/24/2010

r a year."

About Cyclosporine Inhalation Solution

Cyclosporine Inhalation Solution (CIS) is an inhaled formulation of cyclosporine A, an oral medication that has been widely used for over 25 years to prevent rejection in solid organ transplant recipients. Preliminary clinical studies of CIS in lung transplant recipients have been conducted, including a placebo-controlled study that was published as the lead article in the New England Journal of Medicine in January 2006 (Iacono et al 2006). This small, single-center, randomized, controlled, Phase II study showed that administration of inhaled cyclosporine, initiated soon after transplantation, reduced chronic rejection and improved survival while not increasing the risk of infection. This study led to the multi-center, APT Phase III CYCLIST study.

About APT Pharmaceuticals, Inc.

APT Pharmaceuticals, Inc. is focused on the development of cyclosporine inhalation solution (CIS) for the prevention and treatment of chronic rejection in lung transplantation. The company has successfully enrolled a large, multi-center Phase III clinical trial evaluating the effect of CIS on chronic rejection. APT is preparing for study data and commercialization of the product in the US and Europe. Leading life sciences investors Charter Life Sciences, Great Point Partners, InterWest Partners, Pinnacle Ventures, Research Corporation Technologies, Three Arch Partners, Versant Ventures and Vivo Ventures back APT.

Disclaimer

Cyclosporine Inhalation Solution (CIS) is an investigational drug and is not currently approved by the FDA.

For more information about APT, please visit www.aptbio.com.

For more information about the CYCLIST trial, please visit www.cycliststudy.com.

###

'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/7264hm/biomarkers ) has ... "Biomarkers - Technologies, Markets and Companies" ... the broad definition of a biomarker as a ... as an indicator of normal biological or pathogenic ... therapeutic intervention. Tests based on biomarkers have been ...
(Date:6/2/2015)... MALVERN, Pa. , June 2, 2015 /PRNewswire/ ... will be attending the BIO Exhibition 2015 in ... BIO Exhibition, the world,s largest biotechnology gathering, allows ... to high-level executives, where they can evaluate emerging ... has significant eClinical expertise in the design, implementation ...
(Date:6/2/2015)... , June 2, 2015  RXi ... biotechnology company focused on discovering and developing ... dermatology and ophthalmology, today announced that Dr. ... will present at the 23 rd ... world congress will include in-depth presentations by ...
(Date:6/2/2015)... , June 2, 2015 ... global antibiotic resistance problem  MGB Biopharma, ... of anti-infectives, to address the major global problem ... developed a stable intravenous (IV) formulation of MGB-BP-3, designed ... Gram-positive hospital-acquired infections.  The intravenous formulation of ...
Breaking Biology Technology:Global Biomarkers Market Report 2015 - Technologies, Markets and Companies Analysis and Forecasts 2014-2024 2Global Biomarkers Market Report 2015 - Technologies, Markets and Companies Analysis and Forecasts 2014-2024 3YPrime at BIO Exhibition in Philadelphia and DIA in Washington DC during the month of June 2RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 2RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 3RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 4MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections 2MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections 3
... Quest Diagnostics,Incorporated (NYSE: DGX ), the nation,s ... it is scheduled to speak,at the 2007 UBS Global ... 24, 2007. The Quest Diagnostics presentation is scheduled to,begin ... be webcast live during the conference and will be,available ...
... will bike down the California coast to ... and help those affected by arthritis, SAN FRANCISCO, Sept. ... annual Amgen California Coast Classic,Bike Tour on Saturday, September 29 ... over eight days, aim to raise more,than $1.3 million this ...
... ... board, CORAL GABLES, ... new members to the company,s board,of directors. The appointments include a representative ... in the company. Joining the board are Lodewijk J.R. de Vink, ...
Cached Biology Technology:Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference 2More Than 230 Cyclists to Ride in Amgen California Coast Classic Bike Tour to Raise $1.3 Million for Arthritis Foundation 2Stiefel Laboratories Appoints Two New Members to Board of Directors 2Stiefel Laboratories Appoints Two New Members to Board of Directors 3
(Date:5/8/2015)... 8, 2015 Synaptics Inc. (NASDAQ: SYNA ), ... members of the executive management team will present at the ... Media and Telecom Conference Date: May 18, 2015 ... Boston, MA Cowen and Company Technology, ... ET Location: The New York Palace Hotel, New ...
(Date:5/6/2015)... 2015 LifeBEAM, a developer of bio-sensing technology, ... today that they will expand their partnership in bio-sensing ... cycling helmet and the first joint project between the ... in order to give cyclists more style choices and ... and Lazer announced their plan to release a new ...
(Date:4/27/2015)... more than four decades, AUVSI,s Unmanned Systems ... event for the unmanned land, sea, and air industries. ... local, national, or trade news organization interested in gathering ... applications of unmanned technologies. The conference will explore the ... and how it will soon impact the lives of ...
Breaking Biology News(10 mins):Synaptics to Present at Upcoming Investor Conferences 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5
... Cambridge, MA and Corvallis, OR, November 15, 2011 ... that it has entered an agreement with Oregon State ... transcriptome analysis of nine Phytophthora plant ... between BGI and the Phytophthora Genus Sequencing ...
... Europe forests appear evergreen even in the cloudiest conditions, ... overshadowed by a dense canopy. The ability of trees ... intake of carbon for photosynthesis in poor light, has ... British Ecological Society,s Functional Ecology . The ...
... In a review study, researchers from Tufts University ... use of antibiotics in food animals and fish farming ... the preponderance of evidence argues for stricter regulation of ... resistance, notes that a guiding tenet of public health, ...
Cached Biology News:BGI announces collaborative research agreements with Oregon State University 2Trees adapt to poor levels of sunlight to effectively process carbon, study shows 2Evidence supports ban on growth promotion use of antibiotics in farming 2Evidence supports ban on growth promotion use of antibiotics in farming 3Evidence supports ban on growth promotion use of antibiotics in farming 4
Anti-human VEGFR-2/KDR (Protein-A Purified) Polyclonal Antibody...
... exists predominantly as XDH which converts hypoxanthine ... plasma antioxidant. During ischemia, XDH is ... XO by oxidation of essential sulfhydryl groups ... the amino-terminus. AO has a higher ...
Anti-TNKS2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: ELISA, Western Blot...
... Vivaspin 2 bridges the gap between the ... This device combines the speed of the ... and membrane area for superior recoveries from ... choice of PES, Cellulose Triacetate membranes, Vivaspin ...
Biology Products: